When Multiple Genetic Changes Trigger Type 1 Diabetes and Other Autoimmune Conditions

When a 9-year-old boy developed Type 1 diabetes alongside celiac disease and a bleeding disorder, doctors suspected an underlying genetic cause. Genomic testing revealed he carried two distinct pathogenic variants—genetic changes that disrupt normal protein function. One variant affected the CD3G gene, which is crucial for T-cell receptor signaling, a fundamental process in immune system communication. The second affected the TGFBR2 gene, which plays a role in a different immune pathway called TGF-β signaling, as well as blood vessel development.

This combination of genetic changes proved significant because each affects a different aspect of immune regulation. The CD3G variant involved a splice-site change (c.440-2 A>C), meaning it altered how the genetic instructions were being processed, leading to partial CD3γ deficiency. The TGFBR2 change (c.1570G>A; p.Asp524Asn) is known to cause Loeys-Dietz syndrome, a rare condition affecting connective tissue and blood vessel structure.

The clinical picture in this case was striking: the boy developed early-onset Type 1 diabetes, chronic immune thrombocytopenia (persistently low blood platelets), and celiac disease. This specific clustering of autoimmune conditions fits the classification of autoimmune polyendocrine syndrome type 4 (APS-4), a pattern where multiple autoimmune diseases occur in the same individual.

Beyond these three primary conditions, the boy also experienced recurrent severe infections starting in infancy and developed glycogenic hepatopathy (abnormal glycogen accumulation in the liver). Additionally, he showed progressive aortic root dilatation—enlargement of the main blood vessel leaving the heart—which aligns with the vascular complications associated with Loeys-Dietz syndrome.

Researchers proposed that the impaired T-cell signaling from the CD3G variant, combined with disrupted TGF-β pathway activity from the TGFBR2 variant, created a situation where the immune system's normal tolerance mechanisms failed. T-cell signaling and TGF-β signaling are both critical for maintaining self-tolerance—the immune system's ability to distinguish between harmful invaders and the body's own cells. When both pathways are compromised, the risk of autoimmune activation increases substantially.

This case provides evidence for an emerging understanding in immunology: while CD3G deficiency traditionally requires two mutated copies to cause disease, heterozygous variants (one mutated copy) may contribute to immune dysregulation when additional pathogenic variants affecting other immune tolerance pathways are present. In other words, the genetic damage wasn't additive but rather worked synergistically to break down immune control.

This report documents a previously unrecognized link between Loeys-Dietz syndrome and CD3G-related immune dysregulation presenting as autoimmune polyendocrine syndrome type 4. It underscores an important principle: some cases of Type 1 diabetes and other autoimmune conditions may result not from a single genetic defect, but from the interaction of multiple genetic variants affecting different regulatory pathways.

For patients and families, the case highlights the value of comprehensive genetic testing when multiple autoimmune and immunodeficiency features appear together, especially when they begin early in life or occur alongside connective tissue or vascular abnormalities. Understanding the specific genetic mechanisms involved can help guide monitoring and clinical management, even if it does not directly change Type 1 diabetes treatment.

Source: BMC endocrine disorders. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.